Brief: Cyxone Signs LOA With Clinical Contract Research Organization
10/01/2022 08:07
Jan 10 (Reuters) - Cyxone AB CYXO.ST :
* CYXONE STEP UP ACTIVITIES AND EXTEND COLLABORATION WITH
GLOBAL
CRO AROUND RA TRIAL
* LOA IS A KEY STEP FOR ADVANCING CLINICAL PHASE 2B TRIAL OF
RABEXIMOD IN PATIENTS WITH RHEUMATOID ARTHRITIS
* AGREEMENT ENABLES CYXONE TO EXPAND AND INTENSIFY START-UP
ACTIVITIES FOR PHASE 2B TRIAL INCLUDING SITE SELECTIONS AND
REGULATORY SUBMISSIONS ENABLING AN EFFICIENT ROUTE TO ENROLLING
PATIENTS INTO TRIAL WITHIN SHORTEST PERIOD OF TIME
* COMPANY HAS SIGNED LETTER OF AGREEMENT (LOA) WITH
INTERNATIONALLY RENOWNED CLINICAL CONTRACT RESEARCH ORGANIZATION
(CRO) FOLLOWING ON AN EARLY OPERATIONS AGREEMENT (EOA) SIGNED
LAST MONTH
Source text for Eikon: ID:nWkrDLM6t
Further company coverage: CYXO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))